- recruitingPHASE1, PHASE2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
This study is testing a new medicine called BGB-16673 for people with certain types of B-cell cancers, like lymphoma or chronic leukaemia. It aims to find the right dose and see how well it works and if it's safe. It's an early-stage trial.
United States · Australia · Brazil - recruitingPHASE3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
This study offers ongoing access to a drug called ibrutinib for people already using it for certain blood cancers and conditions, who are still benefiting. It also helps gather more long-term information on how safe and effective ibrutinib is.
United States · Argentina · Australia - recruiting
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
This study looks at how a new drug called epcoritamab works for adults with Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) in real-life settings. It aims to see how well it treats these blood cancers when given as part of regular care.
Argentina · Australia · Austria - recruitingPHASE3
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
This study looks at a new drug, golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or not responded to previous treatments. It compares this new combination to standard treatments chosen by doctors.
United States · Australia · Brazil - active not recruitingPHASE3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This study looks at a new drug, tafasitamab, alongside standard treatments for follicular lymphoma and marginal zone lymphoma that have come back or not responded well. It aims to see if adding this new drug works better than the usual treatment alone.
United States · Australia · Austria - active not recruitingPHASE1, PHASE2
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
This study is testing a new medicine called epcoritamab, sometimes with other treatments, for people with B-cell non-Hodgkin lymphoma. Doctors want to check if it's safe and if it helps shrink the cancer. It's given by injection under the skin.
United States · Australia · Belgium - active not recruitingPHASE2
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
This study looks at new treatments, zilovertamab vedotin alone or with nemtabrutinib, for certain B-cell lymphomas like Mantle Cell Lymphoma, Follicular Lymphoma, and Chronic Lymphocytic Leukemia. It checks how safe and effective these treatments are for people whose cancer has returned or didn’t respond to previous therapies.
United States · Brazil · Canada - active not recruitingPHASE3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
This study is for adults with a type of blood cancer called follicular lymphoma, which has come back or isn't responding to treatment. It compares a new drug (Tazemetostat) with existing treatments to see if it's safe and helps people live longer without their cancer getting worse.
United States · Australia · Belgium - recruitingPHASE1
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
This study is looking at a new medicine, LY4584180, for adults with certain blood cancers like lymphoma that have already been treated. We want to see if it's safe, how well it works, and how the body handles it. The study could last about 9 months or more.
United States · France · Germany - recruitingPHASE3
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
This study is testing a new combination of drugs, mosunetuzumab and lenalidomide, for follicular lymphoma. It compares this new treatment to standard chemotherapy for people who haven't had treatment before. The aim is to see if the new combination works better and is safe.
Austria · Belgium · France - recruitingPHASE1
Study of SGR-1505 in Mature B-Cell Neoplasms
This study is testing a new medicine called SGR-1505 for certain types of B-cell lymphoma. We want to find out if it's safe, what dose works best, and if it can help slow down the disease. It's for people whose treatment hasn't worked or stopped working.
United States · France · Italy - recruitingPHASE1
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
This study is testing a new medicine, IKS03, for people with certain types of advanced B-cell non-Hodgkin lymphoma. It aims to find the safest dose and see how well it works. This is an early-stage study, meaning it's the first time it’s being given to people.
United States · Australia · Canada - recruitingPHASE1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
This study is testing a new drug, ABBV-319, for people with certain types of blood cancer like lymphoma or leukemia that have come back or are not responding to current treatments. Researchers want to see if it's safe, how it moves through the body, and if it helps fight the cancer.
United States · Australia · Canada - authorisedPhase II and Phase III (Integrated)
A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in patients with 1L follicular lymphoma.
This study is looking at a new drug called MK-1045, combined with a standard treatment (rituximab), for people newly diagnosed with a type of cancer called follicular lymphoma. Researchers want to see if this new combination is safe and effective in slowing down or stopping the cancer's growth.
France - ongoing, recruitingTherapeutic exploratory (Phase II)
ME-401 combined with rituximab-bendamustine for high-risk and rituximab with a 1:1 randomization to ME-401 for low-risk follicular lymphoma as primary treatment: a phase II study – NLG-FL5 (Follicular lymphoma and ME-401: FLAME)
This study, called FLAME, is looking at a new medicine called ME-401 for people with a type of cancer called follicular lymphoma. It combines ME-401 with standard treatments to see if it works well as a first treatment, for both high and low-risk forms of the disease.
Sweden - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
This study is looking at a new way to treat follicular lymphoma, a type of cancer. It compares a drug called Ibrutinib with a standard treatment, Rituximab. The aim is to see if adding Ibrutinib helps people live longer without their cancer getting worse.
Italy · Greece · Austria - active not recruitingPHASE1, PHASE2
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
This study looks at new drug combinations for follicular lymphoma. It checks how safe they are, how well they work, and how the body handles them. Researchers are comparing different ways to give one of the drugs.
United States · China · France